Posts Tagged ‘diabetes’

Bayer Creates Nintendo Game for Diabetes

Friday, July 24th, 2009

A few weeks ago I was alerted through buzz-tracking site Boing Boing of a new Nintendo plug-in from Bayer called Didget, which helps encourage children with diabetes to build good blood glucose testing habits. It is an incredible example of meaningful marketing and I hope the first of many such examples in the healthcare industry.

While I’m not a child with diabetes, I know a little something about the disease through work with one of our clients, the Glucerna brand at Abbott Nutrition. Several years ago we helped launch a program called Diabetes Control for Life, which helps people manage their disease through better eating, exercise, and regular glucose monitoring. And I have learned how important regular blood glucose testing is for people with diabetes, as it helps people learn about how their body reacts to food and activity. I have actually pricked my finger a few times to test my blood—and I can tell you that it’s not fun for an adult, much less a child. So anything that makes it easier—and even fun—for children to manage their diabetes is a huge opportunity to improve lives through marketing.

Bayer created this program with the help of a parent, Paul Wessel, who noticed that while his son was constantly losing his glucose meter, he always had his Nintendo Game Boy close by. In its final product, Bayer has done a lot of things well. First, it has developed an add-on to an already very popular and widespread Nintendo DS game system. Nintendo was likely very helpful in the development, both because of the revenue upside and chance to do good work. Second, the company created new games that tie into the monitor and reward kids with virtual credits that can be redeemed at a personalized website online. I know my own kids have improved their math and language skills through the educational games we have bought them with similar benefits.

Bayer’s Didget tool lies somewhere between the definitions of “product” and “marketing.” It is a new device that sells for around $50 in the U.K. and comes from Bayer’s family of glucose testing devices (including the Contour brand). I consider the online site and digital prizes part of a meaningful marketing program, much like the Webkinz online experience that is unlocked by purchasing a stuffed animal.

It will be interesting to see if Bayer will quickly expand this program to the U.S. and other countries around the world. I would be interested to see the company commission and share research showing that this device is helping kids learn to test regularly. This could help drive other healthcare companies into a new way of encouraging education, testing, and treatment by making it more fun for children of all ages.

Cheerios Wakes Up to an FDA Warning

Friday, May 15th, 2009

Along with many other people in the marketing world, I was shocked to see that the FDA wrote a warning letter to General Mills, charging that it was making drug-like claims on its Cheerios brand. For two years, the brand has spent tens of millions of dollars on TV, print, packaging, and the Web to advertise the claim that “Cheerios lower your cholesterol 4% in 6 weeks.” The Cheerios brand has been around for decades and many adults and children have been raised on the popular cereal. It has become what its agency, Saatchi & Saatchi, calls a “Lovemark.” But its words seem to have gone too far, and I believe the brand could have done more action to lower cholesterol and improve lives.

In analyzing this case, I first went to my friend and coworker, Jonathan Richman, a former pharma marketer who is now running Business Development at Bridge Worldwide. Richman recently created a new blog, Dose of Digital, where he has attracted a huge following to his posts on pharma and health care digital marketing. He provided some very compelling arguments that the FDA is doing the right thing by questioning the Cheerios claims:

This protects the public because it ensures that there is consistent enforcement of very clear rules for making medical claims in this country. If a pharma company didn’t bother to do a randomized, controlled trial and claimed that their new drug improved cholesterol, there would be an outrage in the public and the FDA would act almost instantly. Why is it different when a cereal company does it? If you let one company get away with it, you embolden others and lose all of the precedent that the FDA has carefully created over the years.”

Richman’s recommendation is for Cheerios to either drop the claim or to invest in the randomized, placebo-controlled trials with tens of thousands of people like pharma companies do. After 2 to 3 years including study time and considerable expense, the brand might have something that it can take to its advertising agency for TV and print ad production.

Richman and other experts predict that Cheerios will press the issue a bit but will eventually have to withdraw its claim and pull the heart off the box, as it should. But it didn’t have to be this way. I believe Cheerios missed an opportunity to make more of a commitment to its consumers by going beyond a claim and developing a program that can make a real, proven difference in people’s lives.

Let me share the example of one of our clients, the Glucerna brand at Abbott Nutrition. Glucerna is a brand of shakes, cereals, and bars for people with diabetes. These products offer a meal replacement or supplement for a group that has to watch its food carefully. Glucerna has a slow-absorbing carbohydrate, among other benefits, which helps avoid blood sugar spikes.

More than seven years ago, the Glucerna brand saw an opportunity to make a meaningful difference in the lives of people with diabetes. In 2002, it created Diabetes Control for Life, a customizable program that helps people change their lifestyle and eat better, exercise more, and measure their blood sugar levels more often. The program does not require people to eat or drink Glucerna, but it suggests meals and snacks where its products are a good choice. Other foods can easily be substituted in the plan.

The company funded a 24-week clinical study to prove the benefits of the program, which were significant:

  • Average of 7.5% weight loss
  • 61% reported lower A1C levels.
  • 73% felt more confident in managing their disease.

Five years ago, we moved the Diabetes Control for Life program to the Web, which includes a very in-depth interactive meal and exercise tracker. We have continually added many other features to help people with diabetes, including a diabetes glossary, discussion board, and ability to IM a dietitian. Traffic continues to increase and other retailers and brands have partnered with us to expand the program.

Cheerios could have done something along these lines. A vast majority of its spending has been on traditional marketing of its claim through mass media. At Cheerios.com there are a few resources for overall cholesterol improvement, essentially a handful of articles and a printable PDF tracking sheet.

With a more comprehensive plan that offers more resources and doesn’t require Cheerios consumption, plus proven test results over many weeks, the brand might have been able to make more than a supposed 4% improvement in cholesterol levels, and it might not have the FDA breathing down its back today.

But it’s not too late! If the brand truly believes that it can make a difference and is truly committed to improving consumers’ health, it can pull back for now, and build out a bigger and better program. So, General Mills, call the lawyers back, pull the claim off the market, and drop us a line if you’re ready to embrace true marketing with meaning.